financetom
Business
financetom
/
Business
/
Lululemon Shares Seen Fairly Valued As Near-Term Momentum Remains Weak
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lululemon Shares Seen Fairly Valued As Near-Term Momentum Remains Weak
Sep 9, 2025 7:49 AM

Lululemon Athletica Inc ( LULU ). reported mixed fiscal second-quarter results, with earnings ahead of expectations but revenue slightly below consensus.

U.S. comparable sales declined for the first time in years, offset by double-digit international growth. Management trimmed its full-year outlook as tariffs, higher markdowns, and elevated inventories weighed on margins.

Following the results, KeyBanc Capital Markets downgraded Lululemon to Sector Weight from Overweight, reflecting the uncertainty surrounding the retailer's near-term performance.

Also Read: Lululemon Stock Tumbles 17% As Tariffs Squeeze Margins

Lululemon now expects full-year revenue of $10.85 billion to $11 billion and full-year earnings of $12.77 to $12.97 per share. Analysts had been anticipating full-year revenue of $11.18 billion and earnings of $14.52 per share, per Benzinga Pro.

KeyBanc adjusted its own forecasts to align with Lululemon's updated guidance. The firm now projects fiscal 2025 revenue of $11.0 billion, down from $11.29 billion previously and slightly below the Street's consensus of $11.07 billion.

Fiscal 2026 revenue is expected at $11.68 billion, a decline from the prior $12.26 billion but roughly in line with analyst estimates.

EPS forecasts were cut more sharply, with fiscal 2025 lowered to $12.90 from $14.74 and fiscal 2026 to $13.16 from $16.31. Both figures fall well below earlier projections.

KeyBanc noted that Lululemon's current valuation does not justify an overweight rating. The stock trades at 12.8 times fiscal 2026 earnings and 7.6 times EV/EBITDA, compared with peer averages of 20.4 and 12.5, respectively. Shares have plunged 56% year-to-date, currently hovering near $168, down 32% from a year ago.

Investors should also consider several risks that could impact Lululemon's performance. Macroeconomic headwinds such as inflation, recessionary pressures, or rising unemployment could curb consumer spending on discretionary items like activewear.

The company's brand strength is critical, leaving it vulnerable to negative publicity or ineffective marketing. Additionally, reliance on third-party manufacturers exposes Lululemon to supply chain disruptions from tariffs, production delays, or broader economic uncertainty.

Price Action: LULU stock is trading lower by 0.72% to $166.89 at last check Monday.

Read Next:

Entrepreneurs Tell A 15-Year-Old The Harsh Truth About Starting A Business

Image by Dani Ber via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enerflex Announcing Extension and Consolidation of Credit Facilities, New Target Leverage Framework
Enerflex Announcing Extension and Consolidation of Credit Facilities, New Target Leverage Framework
Jun 26, 2024
08:55 AM EDT, 06/26/2024 (MT Newswires) -- Enerflex Ltd. ( EFXT ) , which edged up on the TSX yesterday despite losses for the broader market, announced Wednesday the extension and consolidation of its credit facilities and outlined a new target leverage framework. A statement noted that Enerflex ( EFXT ) has entered into an agreement to extend the maturity...
Vir Biotechnology Says FDA Cleared IND Application for Chronic Hepatitis D Drug Combination
Vir Biotechnology Says FDA Cleared IND Application for Chronic Hepatitis D Drug Combination
Jun 26, 2024
08:56 AM EDT, 06/26/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Wednesday the US Food and Drug Administration has cleared its investigational new drug application and granted a fast-track designation for the combination of its drug candidates tobevibart and elebsiran to treat chronic hepatitis D infection. Both drug candidates are currently being evaluated in the company's phase 2...
Market Chatter: Airbus Informs Airlines About Potential Jet Delivery Delays
Market Chatter: Airbus Informs Airlines About Potential Jet Delivery Delays
Jun 26, 2024
08:52 AM EDT, 06/26/2024 (MT Newswires) -- Airbus has warned airlines that some of their jet deliveries that are due in the next two years could be delayed, Bloomberg reported, citing people familiar with the matter. Plane deliveries could be delayed by months from when they were originally due, the people reportedly told Bloomberg. (Market Chatter news is derived from...
Amerigo Resources Maintains 2024 Production Guidance Despite Heavy Rains at MVC Mine in Chile
Amerigo Resources Maintains 2024 Production Guidance Despite Heavy Rains at MVC Mine in Chile
Jun 26, 2024
08:55 AM EDT, 06/26/2024 (MT Newswires) -- Amerigo Resources ( ARREF ) said on Wednesday that its full-year 2024 production guidance remained unchanged despite the impact of heavy rains at its Minera Valle Central (MVC) operation in Chile. The company said disruption caused by heavy rainfall from June 13 to June 23 resulted in a production loss of 1.0 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved